Cargando…
Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models
New innovative vaccines are highly needed to combat the global threat posed by tuberculosis. Efficient components–antigens and adjuvants–are crucial for development of modern recombinant TB vaccines. This study describes a new vaccine (GamTBvac) consisting of two mycobacterial antigen fusions (Ag85A...
Autores principales: | Tkachuk, A. P., Gushchin, V. A., Potapov, V. D., Demidenko, A. V., Lunin, V. G., Gintsburg, A. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409163/ https://www.ncbi.nlm.nih.gov/pubmed/28453555 http://dx.doi.org/10.1371/journal.pone.0176784 |
Ejemplares similares
-
First-In-Human Trials of GamTBvac, a Recombinant Subunit Tuberculosis Vaccine Candidate: Safety and Immunogenicity Assessment
por: Vasina, Daria V., et al.
Publicado: (2019) -
Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study
por: Tkachuk, Artem P., et al.
Publicado: (2020) -
109 Problems and prospects of development of the subunit TB vaccine
por: Tkachuk, A.B., et al.
Publicado: (2014) -
Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2009) -
TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development
por: Kaufmann, Stefan H. E., et al.
Publicado: (2017)